Life Sciences Archive » July, 2025

Life Sciences - July, 2025

184 articles

• FDA Signs Off On Juul E-Cig Products After 5-Year Review
• FDA Warns Firms Over Illegal Kratom Product Marketing
• SEC Fraud Suit Against Ex-Online Pharmacy Execs Advances
• 11th Circ. Says Ex-Quest Diagnostics Worker's FCA Suit Fails
• Stanford Trims Roche IP Suit, But Others Face Most Claims
• Senators Float 'Patent Thicket' Bill To Limit Generic Litigation
• 6 Cases For Patent Attys To Watch In The Second Half Of 2025
• 9th Circ. Decisions Help Clarify Scope Of Legal Lab Marketing
• Ex-CEO Agrees To $27.5M Judgment In Medicare Fraud Case
• $95M Caremark Verdict Should Put PBMs On Notice
• Fla. AG, Sandoz Clash With Other Enforcers Over 'Done' Deal
• PE Firm Is Denied FDA Docs For Defense In Deal Challenge
• J&J Loses Bid To DQ Beasley Allen From Talc MDL Committee
• Biotech Collaborations Can Ease Uncertainty Amid FDA Shift
• Iowa Church Says DEA Can't 'Pocket Veto' Drug Exemption
• Playing Mah-Jongg Makes Me A Better Mediator
• Pharmacy Benefit Managers Say Ohio Can't Recast Suit
• Gilgo Beach Killer Case Puts New DNA Science To The Test
• Hims & Hers Brass Face Suit Over 'Knockoff' Wegovy Sales
• Does Research Tool Safe Harbor Cover AI Drug Development?
• Glucose Monitoring Co. LifeScan Hits Ch. 11 With $1.7B Debt
• Novartis Denied Bid To Block Generic Entresto In TM Feud
• CooperSurgical Wants Conn. Embryo Loss Claims Tossed
• Law School's Missed Lessons: Navigating Client Trauma
• GTCR Seeks Rival's Sales Data To Counter FTC Challenge
• Biohaven's Drug Prospects Were Overhyped, Suit Says
• Trump Admin Seeks Win In Harvard $2B Funding Freeze Case
• Patent Fight Over Xtandi Erupts Anew Before RFK Jr.
• Court Blocks Generic Selenium Products Amid Patent Suit
• The Biggest IP Agency Developments Of 2025: Midyear Report
• Split 4th Circ. Rejects GenBioPro Abortion Ban Challenge
• 9th Circ. Backs Nature's Way Loss In Supplements TM Suit
• Abbott Brass Ignoring Call For Formula Plant Probe, Suit Says
• Fed. Circ. Temporarily Blocks MSN's Entresto Generic
• J&J Demands Sanctions Over Atty's 'Frivolous' Bias Suit In NJ
• 4 Former Justices Would Likely Frown On Litigation Funding
• PTAB Knocks Out Claims In 3 Nasal Airway Patents
• DOJ Drops Vax Card Case Against Plastic Surgeon Mid-Trial
• USPTO Acting Director Spurns 'Traditional Knowledge' Treaty
• Judge Says Med Device 401(k) Fee Suit Should Get A Trim
• Fed. Circ. Upholds PTAB Ax Of J&J Unit's Catheter Patent
• 2nd Circ. Affirms Biotech Founder's Win In Trading Suit
• Tevra Asks 9th Circ. To Revive Bayer Flea, Tick Meds Suit
• J&J Unit Follows Fed. Circ. Win With Schizophrenia Drug Suits
• Mich. Jury Sides With Red Cross In COVID Vax Refusal Suit
• Masimo Corp. Settles Investor Suit Over Revenue Disclosures
• Aetna, CVS Can't Dodge $21M Payment Battle, Lab Says
• How Attys Can Use AI To Surface Narratives In E-Discovery
• Kirkland, Wachtell Guide $17.5B Waters-BD Life Sciences Deal
• DOJ Sends Warning In Gender Care Provider Subpoenas
• Catching Up On Stewart's Discretionary Denial Decisions
• AbbVie Defeats Investor Class Suit Alleging Humira Kickbacks
• Amgen Eyes New Trial After Regeneron's $407M Antitrust Win
• Courts Face Early Push To Expand Justices' Injunction Ruling
• Success Tricking FDA Shouldn't Protect Merck, Justices Told
• Fed. Circ. Questions Patent Ownership After J&J's $20M Loss
• 3rd Circ. Revives Benicar MDL Fees Suit Against NJ Law Firm
• Fired Red Cross Vax Refuser Seeks $6M As Jury Trial Wraps
• Leveraging Diligence Findings For Better Life Sciences Deals
• Court Says Olympic Runner Treated Unfairly In Testing Appeal
• The Biggest TM Rulings Of 2025: A Midyear Report
• Merck's $10B Pulmonary Power Play Is Among Its Top 5 Deals
• IP Due Diligence Tips For AI Assets In M&A Transactions
• MSN Beats Novartis' Patent Suit Over Entresto
• Walgreens Boots Shareholders Approve $24B Sycamore Deal
• Quinn Emanuel Sanctioned For Ad Case 'Misrepresentations'
• How McKesson Ruling Will Inform Interpretations Of The TCPA
• Better Therapeutics Settles SPAC Suit In Del. For $1M
• Cancer-Focused BridgeBio's $949M SPAC Deal Gets SEC Nod
• AbbVie Frees Taxpayers From M&A Capital Loss Limitations
• 2 Firms Tapped To Lead Regeneron Investor Suit
• Taxation With Representation: Davis Polk, Kirkland, Cassels
• Drugmaker Fights Claims Over 'Misleading' IPO Statements
• New USPTO Leadership Must Address Low-Quality Patents
• Chhabria's Privacy Ruling An 'Outlier,' Judge Tells Tech Giants
• Boehringer Wins Another Zantac Cancer Trial In Illinois
• Execs Of Device Co. Made $6M From Insider Trading, Suit Says
• Fed. Circ. Backs Novartis PTAB Win Over Shilpa MS Patent
• Vax Refuser Tells Jury Red Cross Mandate Was 'Unsettling'
• WilmerHale, US Trustee Spar Over Work In 23andMe Ch. 11
• High Court Must Overrule Outdated Patent Eligibility Doctrine
• Jazz Looks To Block Avadel From Asking For Sleep Drug OK
• Playing The Violin Makes Me A Better Lawyer
• AbbVie Pays Up To $2B For Oncology Licensing Agreement
• Google Notches Deal With Flo Users Ahead Of Privacy Trial
• J&J Unit Owes $76.6M For Ending AI Tissue Imaging Deal
• Venture-Backed MedTech Firm Shoulder Innovations Files IPO
• J&J Seeks To Toss 'Nowhere Close' Band-Aid PFAS Suit In NJ
• The State Of AI Adoption In The Patent Field
• Purdue Case Could Transform Patent Obviousness Analyses
• Sandoz, Buyers Defend $275M Deal Amid State Objections
• Fed. Circ. Cements Arthrex PTAB Wins Over Medical Device IP
• 10th Circ. Won't Rule On Immunity In Dental Dispute
• Federal Regs Order May Spell Harsher FDCA Enforcement
• Law School's Missed Lessons: Practicing Self-Care
• Freshfields Guides Merck's $10B Deal For Verona Pharma
• IRhythm Argues Patent Owner's Inaction Shouldn't Doom IPRs
• Breaking Down Stewart's Nonstop Discretionary Denial Orders
• Medtronic's Blood Pressure IP Claims Against Recor Get Axed
• Product Liability Cases To Watch In 2nd Half Of 2025
• Chinese Man Arrested Over COVID Data Theft, Law Firm Hack
• Omnicare, CVS Tab In FCA Case Increases To $949M
• Trump Declares 50% Copper Tariff, Floats 200% Pharma Tariff
• Teva Challenge To J&J Antipsychotic Patent Fails At Fed. Circ.
• Mylan Securities Class Action Over W.Va. Plant Will Proceed
• Biosimilars Industry Group Backs Interchangeability Bill
• Anoxia Says Alembic's Blood Clot Catheter Infringes Patents
• 4th Circ. Revives Medical Device Co.'s Claim In Contract Suit
• Wash. Law Firm Settles Investors' Suit Over $1M Escrow Loss
• Masimo Criticizes Bid To DQ Quinn Emanuel In Payout Suit
• Medical Co. Wants High Court To Review Rushed Patent Case
• Vaxart Investors Can Pursue Suit Over COVID Vax Claims
• High Court Allows Trump's Gov't Cuts And Restructuring
• ABA Opinion Makes It A Bit Easier To Drop A 'Hot Potato'
• IRhythm IPR Denial Raises Key PTAB Discretion Questions
• Annoyed Fed. Circ. Judge Unsure Where To Land In Drug Row
• Fed. Circ. Digs Into Domestic Industry For Apple Watch Appeal
• Pregnant Doc, Medical Orgs. Sue To Block RFK's Vax Directive
• Fitch Even Fights Bid To Toss Prenatal Test Patent Suit
• Calif. Fails To Pause 23andMe's Sale During Appeal
• Kirkland-Led Zenyth Partners Raises $375M For Latest Fund
• Ex-Leerink Banker Can't Get Redo On Unpaid Bonuses Claim
• USPTO Ups Number Of Prioritized Patent Applications
• P&G Beats False Ad Suit Over 'Pure Cotton' Tampax, For Good
• Catching Up With Delaware's Chancery Court
• Canadian Suit Offers Disclosure Lesson For US Cannabis Cos.
• J&J Unit Looks To Wipe Out $442M Catheter Antitrust Loss
• Stewart Drops Mixed Bag Of Discretionary Denial Rulings
• Genentech's $122M MS Drug Royalties Case Ends In Mistrial
• Implant Co. Sues Zimmer Biomet In Del. Over Milestone Miss
• Anthem Dodges Most Claims In Lab's $3.8M Insurance Suit
• IPR Denial In IRhythm Should Not Set A Blanket Rule
• What High Court's Tenn. Trans Care Ruling Means Nationally
• Circuit-By-Circuit Recap: Justices Send Message To Outliers
• How Trump's Trade Policies Are Shaping Foreign Investment
• States Still Oppose Florida's Generic Drug Deal With Sandoz
• The Moments That Shaped The Universal Injunction Case
• Natera Inks $8.25M Deal To End Prenatal Tests Suit
• TRESemme Buyers' Claims Too Tangled For Class Cert.
• Zimmer Biomet Bone Cement Doesn't Bond, NC Suit Says
• My Opera And Baseball Careers Make Me A Better Lawyer
• High Court Passes On Mont. Abortion, Parental Consent Case
• HHS Ordered To Restore Data Axed Under 'Gender Ideology' EO
• Medela Can't Escape Trade Dress Claim In Breast Pump Suit
• What To Watch In Mass. Courts In The Second Half Of 2025
• The Firms That Won Big At The Supreme Court
• Breaking Down The Vote: The High Court Term In Review
• Capital Markets Upturn Sets Stage For Second-Half Rebound
• The Biggest Patent Rulings Of 2025: A Midyear Report
• Genentech's $122M IP Fight Against Biogen In Jury's Hands
• Judge Revives Supplement Patent Claims Jury Found Invalid
• Vax Maker Ends Appeal After Stewart Halts Patent Ax Sanction
• 2nd Circ. Affirms NY Court Can't Nix Swiss Arbitration Loss
• DOJ, HHS Form New False Claims Act Enforcement Group
• Supply Co. Owner Charged In $5.4M Medicaid Fraud Scheme
• High Court Case Tops List of Securities Appeals To Watch
• Ex-Employees Of NJ Medical Co. Must Face Trade Secrets Suit
• Top Product Liability News In H1 2025
• Subject Matter Eligibility Test Should Return To Preemption
• 8 Ways Lawyers Can Protect The Rule Of Law In Their Work
• GOP Reps. Want Probe Of RI Judge Blocking Funding Freeze
• The Funniest Moments Of The Supreme Court's Term
• Wisconsin High Court Narrowly Blocks 1849 Abortion Ban
• Alnylam Pharma Beats Inventorship Suit Tied To COVID-19 Jab
• 10 States Challenge Asbestos Claim Doc Purge Plans
• Mallinckrodt Execs See Securities Fraud Claims Trimmed
• 5 Federal Circuit Clashes To Watch In July
• 4th Circ. Affirms CVS Win In Vaccine Injury Suit
• The Sharpest Dissents From The Supreme Court Term
• Full Fed. Circ. Rejects Mylan Rehearing Bid In Patent Case
• Justices Face Busy Summer After Nixing Universal Injunctions
• Monthly Merger Review Snapshot
• Judge Tosses Teva Suit Over Generic Drug Patent Deal
• Unvaccinated Ex-Staffer Can Pursue Leaked Health Info Claims
• Is SEC Moving Away From Parallel Insider Trading Cases?
• Rising Enforcement Stakes For Pharma Telehealth Platforms
• Law School's Missed Lessons: Communicating With Clients
• Top Personal Injury, Med Mal News: 2025 Midyear Report
• Dentons Adds Career Arnold & Porter Litigator In DC
• 3 Judicial Approaches To Applying Loper Bright, 1 Year Later
• RI Judge Orders Halt To HHS Layoffs, Reorganization
• Fed. Circ. Won't Revisit Jepson Claim Ruling In Xencor IP Case
• Judge Rejects Integra Investor's Suit Over Factory Issues
• Fed. Circ. Faults PTAB Ax Of Patent On Bausch Eye Drops